Home' Trinidad and Tobago Guardian : November 10th 2014 Contents A28
body & soul
Guardian www.guardian.co.tt Monday, November 10, 2014
EXPRESSIONS OF INTEREST
Engagement of an Operator for a Cafeteria at the Family Court and/or Hall of
Justice of the Judiciary of the Republic of Trinidad and Tobago
The Judiciary of the Republic of Trinidad and Tobago is seeking Expressions of Interest (EOI) from
qualified caterers wishing to be considered for inclusion in tenders for the award of a contract for the
provision of a full catering cafeteria for two (2) meals (breakfast and small lunches) including non
/or Hall of Justice
premises five (5) days a week for staff, visitors and any others who may perform business with the
Judiciary. The Judiciary will evaluate all EOI submissions and determine a shortlist of companies who will
be invited to bid on a three (3) year performance based contract.
Suppliers will be pre-qualified based on the following criteria:
Legal and Statutory Requirements
All interested vendors are asked to visit http://www.ttlawcourts.org/tenders
For full instructions on submission of Expressions of Interest Engagement of an Operator for a
Cafeteria at the Family Court and/or Hall of Justice of the Judiciary of the Republic of Trinidad and
Any inquires may be directed to firstname.lastname@example.org attention: Ms. Josanne Teeluckingh,
Procurement Specialist, Judiciary.
The Judiciary reserves the right to accept or reject any and all submissions.
All proposals will remain confidential, subject to the Freedom of Information Act, 1999.
A group of scientists including three Nobel lau-
reates in medicine has proposed that US health
officials chart a new path to developing Ebola drugs
and vaccines by harnessing antibodies produced
by survivors of the deadly outbreak.
The proposal builds on the use of "convalescent
serum," or survivors blood, which has been given to
at least four US Ebola patients who then recovered
from the virus. It is based on an approach called
passive immunisation, which has been used since
the 19th century to treat diseases such as diphtheria
but has been largely surpassed by vaccination.
The scientists propose using new genetic and other
technologies to find hundreds or thousands of different
Ebola antibodies, determine their genetic recipe, grow
them in commercial quantities and combine them
into a single treatment analogous to the multi-drug
cocktails that treat HIV/Aids.
That contrasts with current drug development,
which focuses on finding one molecule, or a small
number, to defeat the Ebola virus that has killed
nearly 5,000 people in West Africa and infected
thousands more since March.
Nobel laureates David Baltimore, an expert in the
molecular biology of the immune system, James Wat-
son, co-discoverer of the double helix that is DNA,
and Jim Simons, who founded hedge-fund Renais-
sance Technologies and was a pioneer in the quant
revolution on Wall Street, are among the advocates
of the idea. It was outlined in a letter that was reviewed
The proposal was sent to officials at the Department
of Health and Human Services, including the Food
and Drug Administration, to lawmakers and to biotech
companies. They have not responded, said geneticist
Michael Wigler of Cold Spring Harbor Lab, who
wrote and gathered signatures for the position paper.
The recipients did not respond to Reuters requests
for comment on Friday.
The scientists urged government leadership without
offering a specific development or production plan,
and it is not clear whether the idea would offer a
faster track to success than current efforts.
Although there is no proof that blood from survivors
helps Ebola patients survive, it is known that patients
recover when their own blood produces enough anti-
bodies to stop the virus.
Antibodies are proteins produced by the immune
system to fight bacteria, viruses, and other invaders,
from colds to measles. Giving antibodies to infected
people would offer their immune systems a head
start in fighting Ebola, the theory goes.
If the antibodies in survivors blood is genetically
sequenced, they would provide a recipe for treatments,
which could be produced with technologies already
used to manufacture antibodies that target cancer
or rheumatoid arthritis, the scientists said.
"It would cost less than $1 million to get the genetic
sequences of the antibodies from people who have
recovered, and then we would have an armamentarium
of hundreds or even thousands of antibodies," Wigler
He speculated that the idea has not gained traction
before because "academics are trained to overlook
the obvious." The approach would be difficult, and
"many people in this day and age are afraid to risk
failure," he said.
Ebola experts were cautious about the possibility
that hundreds of anti-Ebola antibodies would prevent
or cure infections.
Studies have shown that some antibodies that
neutralise Ebola virus in test tubes don t protect
infected lab animals, said Dr Thomas Geisbert of the
University of Texas Medical Branch, who is working
on Ebola vaccines. He also questioned whether the
proposal would save time, given the need to test any
antibody cocktail in both lab animals and human
One of the most promising experimental
treatments, Mapp Biopharmaceutical s
ZMapp, consists of three different antibodies
produced by mice infected with Ebola. Initial
research was published in 2000, but it took
until this summer for a study to show that
ZMapp cured Ebola-infected lab monkeys.
GlaxoSmithKline Plc (GSK.L) and Johnson
& Johnson (JNJ.N) are among the drug-
makers working on an Ebola vaccine. Both
declined to comment on whether the anti-
bodies proposal might be effective against
European researchers separately are plan-
ning to test whether Ebola survivors serum
can cure patients, starting this month. But
relying on transfusions of survivors blood
for those antibodies is a daunting task in
West Africa, given the need to screen it for
other diseases and ensure health workers
aren t exposed during the collection or infu-
By contrast, "it takes a very short time"
to produce countless copies of antibody
genes, said molecular biologist Michel
Nussenzweig of the Rockefeller University.
"Hundreds are not a problem; this has been
automated," he said. However, he questioned
whether hundreds would be necessary to
Wigler s answer: the Ebola virus is mutat-
ing. That might thwart a three-antibody
cocktail like ZMapp, he said, but it is highly
unlikely that the targets of hundreds of anti-
bodies would all mutate. A diversity of anti-
bodies "mimics the body s own defences
and could overcome mutations in the virus
that may develop," he said. (Reuters)
Find recipe for Ebola cure in survivors' blood
Scientists tell US:
YOUR DAILY HEALTH
News and Advice
The Ebola virus is transmitted
through direct contact with the
bodily fluids of those infected. One
group of scientists is proposing
that health officials harness
antibodies produced by survivors.
Links Archive November 9th 2014 November 11th 2014 Navigation Previous Page Next Page